Revenue Breakdown
Composition ()
No data
Revenue Streams
Valneva SE (VALN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is IXIARO, accounting for 56.1% of total sales, equivalent to €54.70M. Other significant revenue streams include DUKORAL and Third party products. Understanding this composition is critical for investors evaluating how VALN navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Valneva SE maintains a gross margin of 51.66%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -17.25%, while the net margin is -21.34%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively VALN converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, VALN competes directly with industry leaders such as CMPS and IMMP. With a market capitalization of $814.53M, it holds a leading position in the sector. When comparing efficiency, VALN's gross margin of 51.66% stands against CMPS's N/A and IMMP's 100.00%. Such benchmarking helps identify whether Valneva SE is trading at a premium or discount relative to its financial performance.
